Literature DB >> 26433613

The R900S mutation in CACNA1S associated with hypokalemic periodic paralysis.

Qing Ke1, Fangping He1, Lingping Lu2, Ping Yu2, Yajian Jiang3, Chen Weng4, Hui Huang5, Xin Yi5, Ming Qi6.   

Abstract

Primary hypokalemic periodic paralysis is an autosomal dominant skeletal muscle channelopathy. In the present study, we investigated the genotype and phenotype of a Chinese hypokalemic periodic paralysis family. We used whole-exome next-generation sequencing to identify a mutation in the calcium channel, voltage-dependent, L type, alpha subunit gene (CACNA1S), R900S, which is a rare mutation associated with hypokalemic periodic paralysis. We first present a clinical description of hypokalemic periodic paralysis patients harboring CACNA1SR900S mutations: they were non-responsive to acetazolamide, but combined treatment with triamterene and potassium supplements decreased the frequency of muscle weakness attacks. All male carriers of the R900S mutation experienced such attacks, but all three female carriers were asymptomatic. This study provides further evidence for the phenotypic variation and pharmacogenomics of hypokalemic periodic paralysis.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CACNA1S; Hypokalemic periodic paralysis; Muscle channelopathy; R900S mutation

Mesh:

Substances:

Year:  2015        PMID: 26433613     DOI: 10.1016/j.nmd.2015.09.006

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  2 in total

1.  PharmGKB summary: very important pharmacogene information for CACNA1S.

Authors:  Katrin Sangkuhl; Robert T Dirksen; Maria L Alvarellos; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2020-02       Impact factor: 2.000

2.  Gating pore currents occur in CaV1.1 domain III mutants associated with HypoPP.

Authors:  Fenfen Wu; Marbella Quinonez; Stephen C Cannon
Journal:  J Gen Physiol       Date:  2021-08-31       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.